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RESUMEN
Objetivo: El propósito de este trabajo fue desarrollar un proceso sintético para la obtención del compues-
to con actividad antitumoral TAP7f a escala de gramos para su uso en estudios preclínicos.
Método: Se emplearon estrategias de química en solución, para reemplazar la ruta sintética original en 
fase sólida, a fin de hacer más rentable el proceso.
Resultados: TAP7f se pudo obtener a partir de un material de partida económico, L-phe, en cinco pasos 
y utilizando menores cantidades de reactivos, haciendo que este nuevo proceso sea más adecuado para 
la producción a gran escala.
Conclusiones: Hemos demostrado que este nuevo procedimiento es una ruta más eficiente y económica 
para sintetizar la molécula objetivo a gran escala.
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ABSTRACT
Purpose: The purpose of this work was to develop a synthetic process to obtain the compound with 
anti-tumor activity, TAP7f, on a gram scale, for preclinical studies.
Method: Solution chemistry strategies were used to replace the original synthetic solid phase route to 
make the process more profitable.
Results: TAP7f was obtained from an inexpensive starting material L-phe, in five-steps and using less 
amounts of reagents, rendering this new process more amenable to the large-scale production.
Conclusions: We have demonstrated that this new, procedure is a more efficient and economical route to 
synthesize the target molecule in large scale.
Keywords: antitumoral; scale-up; Triazolyl peptidyl penicillins
Artículo Original 
Original Article
Correspondencia 
Correspondence
Patricia Griselda Cornier
cornier@iquir-conicet.gov.ar
Financiación 
Fundings
Conflicto de interés 
Competing interest
The author confirm that this article 
content has no conflict of interest.
Agradecimientos 
Acknowledgements
The author wishes to acknowledge to 
the Universidad Nacional de Rosario for 
financial support. Special thanks to Dr. 
Ernesto G. Mata for careful proofreading 
the manuscript.
Received: 20.04.2020 
Accepted: 06.05.2020
Scale-up synthesis of TAP7f, an antitumoral triazolyl peptidyl penicillin
Escalado de la síntesis de TAP7f, una triazolilpeptidil-penicilina con actividad antitu-
moral
Patricia Griselda Cornier1
1 Universidad Nacional de Rosario, Facultad de Ciencias Bioquímicas y Farmacéuticas, Departamento de Química Orgánica, Área Química Medicinal, 
Rosario, Argentina.
http://dx.doi.org/10.30827/ars.v61i3.15210
170 Ars Pharm. 2020; 61(3): 169-173
Cornier PG
INTRODUCTION
Triazolyl peptidyl penicillins (TAPs) are novel hybrids 
compounds with promising antitumoral activity.(1,2) TAPs 
structures are constituted by a penicillanic core linked to 
a peptide portion via a triazole group. These previously 
reported structures were synthesized through a well stab-
lished solid-phase methodology, that allowed to obtain a 
small library with good yields.
In a preceding study,(2) we reported that derivative contain-
ing the dipeptide Leu-Phe (TAP7f, Figure 1), behaves as a 
selective and potent antitumor agent that induces an apop-
totic response.(3,4) In order to support downstream research 
activities with this candidate, we were initially requested to 
prepare increasing amounts of TAP7f. Herein we describe 
the strategy chosen to achieve that goal.
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Figure 1. TAP7f structure
The solid-phase peptide synthesis has been widely used and 
developed since its description in 1963 by Merrifield.(5) The 
methodology is based on attaching the amino acid, through 
the terminal carboxyl group, to an insoluble polymeric sup-
port and the following amino acids are subsequently cou-
pled. The solid-phase peptides synthesis follows a general 
pattern of repetitive coupling-washing-deprotection-wash-
ing cycles.(6)
Some of the most important advantages of this method-
ology are: easy elimination of excess reagents, simplified 
purification by washing the solid support, and easy auto-
mation of the synthetic route. Solid-phase chemistry al-
lows the generation of a wide variety of compounds, in a 
straightforward manner and in relatively short periods of 
time.(7) Generally, this methodology is used to synthesize 
small amounts of many different compounds. When pre-
clinical studies begin to be planned, larger quantities of the 
selected candidates are required. Unfortunately, for scale-
up purposes, the common resins generally employed in 
solid-phase and combinatorial chemistry are quite expen-
sive and impractical considering the waste of the polymer 
support. Therefore, from the economic point of view, the 
solution phase approach retains its usefulness for obtain-
ing substances of interest, specially at a gram scale. Here, 
we present our solution phase strategy to obtain TAP7f in 
large scale.
RESULTS AND DISCUSSION
In the optimized previously reported solid phase synthe-
sis of TAP7f(1), Wang resin-bound Fmoc-phenylalanine (1, 
Scheme 1) was used as the starting material.
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Scheme 1. Initial reported solid phase synthesis of TAP7f
To replace this solid support, commercial enantiomerically 
pure L-phenylalanine was used. This is the step with the 
greatest impact in reducing the total cost of the process, 
since L-phenylalanine is approximately 45 times less ex-
pensive than the solid supported one.
TAP7f has its carboxylic acid group protected as methyl es-
ter. This transformation was achieved with diazomethane 
at the final stage of the solid-phase strategy. Diazomethane 
reactions tends to be highly selectively, giving quite pure 
products in high yields, but on larger scales, the reaction is 
mostly avoided due to safety concerns.
Designing the synthesis process in solution phase, we real-
ized that methylation of phenylalanine free acid had to be 
the first step to carried out to obtain TAP7f.
Thus, ester 6 (Scheme 2) was prepared treating L-Phe with 
2 equiv of p-toluenesulfonic acid monohydrate in metha-
nol,(8) and the resulting solution was boiled under reflux for 
18 h. Evaporation to dryness and trituration of the residue 
with ether yielded L-Phenylalanine methyl ester p-tolue-
nesulfonate (6) as white solid. This salt was used for the 
next step without further purification.
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Scheme 2. New synthetic strategy of TAP7f in solution phase
Then, the coupling of protected leucine, the second ami-
no acid, was carried out under standard conditions. For 
this step, Boc protecting strategy was chosen since it is 
cleavable under acidic conditions, releasing only volatile 
by-products. Synthesis of 7 was performed using only 1.1 
equiv. of N-(3-Dimethylaminopropyl)-N′-ethylcarbodiim-
ide hydrochloride (EDC:HCl) as the coupling agent, and 
1-hydroxybenzotriazole (HOBt) as a racemization suppres-
sant. In this way, less amount of reagents were used for the 
same reaction with respect to the solid phase strategy.
After Boc deprotection, optimization of the alkyne coupling 
to the molecule was the next challenge. Table 1 summarizes 
the results of the different reagents investigated. In the sol-
id phase route, 20 equiv of DIC was used to the coupling 
step. To optimize and decrease the amounts of reagents 
used, we start testing dicyclohexylcarbodiimide (DCC)(9) 
and diisopropylcarbodiimide (DIC)(10) in lower amounts. 
Yields were good, but purification was complicated, due 
to the insoluble urea byproducts. When EDC.HCl(11,12) was 
used as a coupling agent, yields were very low. For fur-
ther optimization, we decided to explore the reaction with 
2-ethoxy-1-ethoxycarbonyl-1,2-dihydroquinoline (EEDQ).
(13) Fortunately, employing 1.1 equiv of this reagent, per-
formance was similar to that obtained with DIC, but using 
smaller amounts of reagent and avoiding the undesirable 
urea byproducts.
Table 1. Different alkyne coupling conditions for the solution phase route
Entry Coupling reagent Equiv. solvent and other reagents Yield (%) Ref.
1 DCC 1.1 DCM 78* 9
2 DIC 1.1 DIPEA/DCM/DMF 50* 10
3 EDC.HCl 2 DCM DIPEA 7 11
4 EDC.HCl 2 DCM/DMF/DIPEA - 12
5 EEDQ 1.1 DCM 66 13
* Urea by-products were difficult to remove
Then, the final stage involved the assembly of the penicillin 
azide 4 to the alkyne 8 with the Cu-catalyzed 1.3 dipolar cy-
cloaddition. After 3 h of reaction, TAP7f was obtained with 
74% for this final step, after chromatographic purification.
A comparison of the two synthetic strategies to obtain 
TAP7f is shown in Table 2.
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Table 2. Comparison of the two synthetic strategies
Entry Topic Solid phase synthesis Solution phase synthesis
1 Steps 7 5
2 Global yield 49 33
3
Starting material cost (to 
synthesize 1g of product)
Fmoc-Phe Wang resin
(4 g, 0.7mmol/g loading U$D 
530)*
L-Phe
(0.8 g  U$D 2)*
4
Aminoacid coupling 
reagents
HOBt (3 equiv.)
EDC.HCl (3 equiv.)
HOBt (1.1 equiv.)
EDC.HCl (1.1 equiv.)
5 Alkyne coupling step
DIC 20 (equiv)
propiolic acid (10 equiv)
EEDQ (1.1 equiv)
propiolic acid (1.1 equiv)
6 Time (h, global process) 25.5 47.5
7
Cromatographic purifi-
cations
1 3
*obtained from Aldrich (catalog n°47666 and n°P2126)
With this new strategy, TAP7f can be prepared from a read-
ily available, inexpensive starting material such as L-Phe 
and using less amounts of reagents for the intermediate 
steps, rendering this new process more amenable to the 
large-scale production.
EXPERIMENTAL
Solvents were analytical grade or were purified by stand-
ard procedures prior to use. Infrared spectra (IR) were re-
corded on a Shimadzu Prestige 21 spectrophotometer and 
only partial spectral data are listed. The 1H and 13C NMR 
spectra were acquired in the specified solvent, in a Bruker 
Avance spectrometer (300 and 75 MHz for 1H and 13C, re-
spectively), with tetramethylsilane (TMS) as internal stand-
ard. The chemical shifts (δ) are reported in ppm downfield 
from TMS and coupling constants (J) are expressed in 
hertz. Flash column chromatography was performed using 
Merck silica gel 60 (230-400 mesh). Elution was carried out 
with hexane-EtOAc mixtures, under positive pressure and 
employing gradient of solvent polarity techniques.
Typical Procedure
L-phenylalanine methyl ester p-toluenesulfonate (6). A 
suspension of L-phenylalanine 5 (2.01 g, 12.16 mmol) in 
methanol (20 mil) was treated with p-toluenesulfonic acid 
monohydrate (4.52 g, 24.32 mmol), and the resulting solu-
tion boiled under reflux for 24 hours. Evaporation to dry-
ness and trituration of the residue with ether followed by 
washing with ether yielded 6 (3.84 g, 90%), and it was used 
in the next step without further purification. RMN de 1H 
(CDCl3, 300MHz) δ 2.32 (s,CH3), 3.11(m, 2H,CH2), 3,46 (s, 
3H, OCH3), 4,26 (m, 1H, CH), 7.00-7.71 (m, 9H arom.), 8.13 
(s, 2H, NH3+), RMN de 13C (CDCl3, 75MHz) δ 21.3 (CH3), 
36.9 (CH2), 52.9 (OCH3), 126.7 (CH), 127.5 (CH), 129.6 (CH), 
134.6 (C), 140.8(C), 165.6 (CO), 169.4 (CO).
Methyl (tert-butoxycarbonyl)-L-leucyl-L-phenylala-
ninate (7). Compound 6 was dissolved in DCM and cooled 
to 0°C. Boc-Leu (1.1 equiv.), EDC.HCl (1.1 equiv), HOBt (1.1 
equiv) and DIPEA (3.5 equiv) were added. The mixture was 
allowed to warm to room temperature and stirred for 24 h. 
After this time, a solution of NaHCO3 was added and the 
mixture was extracted with AcOEt (2x 30ml). The organ-
ic phase was dried with Na2SO4 and concentrated under 
high vacuum. The resulted crude product was purified by 
column chromatography (hexane:AcOEt) to yield 7 (3.14g, 
75%). RMN de 1H (CDCl3, 300MHz) δ 0.91 (m, 6H, 2 CH
3), 
1.43 (s, 9H, 3CH3), 1.52-1.66 (m, 2H, CH2), 3.12(m, 2H,CH2), 
3,70 (s, 3H, OCH3), 4,06 (m, 1H, CH), 4.84 (m, 1H, CH), 7.08-
7.31 (m, 5H arom.), 7.68 (s, 1H, NH), 8.03 (s, 1H, NH), RMN 
de 13C (CDCl3, 75MHz) δ 23.9 (CH3), 25.8 (CH3), 28.2 (CH3), 
37.8 (CH2), 41.3 (CH2), 52.4 (OCH3), 53.1 (CH), 53.5 (CH), 
80.7 (C), 136 (C), 155.6 (CO), 173 (CO).
Methyl propioloyl-L-leucyl-L-phenylalaninate (8). Com-
pound 7 was deprotected with TFA:DCM (1:1) in 30 min. 
After evaporation, the residue was dissolved in DCM at 
0°C. Then EEDQ (1,1 equiv), propiolic acid (1.1 equiv) and 
DIPEA (2 equiv) were added and the mixture was stirred 
for 2 h, and washed with 2.5 M HCl (2x30ml) and dried 
(Na2SO4). After filtration, the residue was purified by col-
umn chromatography (hexane:AcOEt) to give 8 (1.81g, 
66%, 2 steps). RMN de 1H (CDCl3, 300MHz) δ 0.86 (m, 6H, 
2CH3), 1.49 (m, 2H, CH2), 1.56 (m, 1H, CH), 2.05 (s, 1H, CH), 
3.07(m, 2H,CH2), 3,70 (s, 3H, OCH3), 4,50 (m, 1H, CH), 4.80 
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(m, 1H, CH), 6.32 (s, 1H, NH), 6.69 (s, 1H, NH), 7.05-8.07 
(m, 5H arom). RMN de 13C (CDCl3, 75MHz) δ 22.1 (CH3), 
22.3 (CH3), 20.7 (CH), 25.4 (CH), , 38.7 (CH2), 41.1 (CH2), 
51.6 (CH), 52.3 (OCH3), 53.2 (CH), 77.2 (C), 108 (CH), 120.6 
(CH), 125.6 (CH), 128.7 (CH),135.5 (C), 143.5 (CO), 158.9 
(CH), 163.5 (CO), 171.9 (CO).
M e t h y l ( 1 - ( ( ( 2 S ) - 6 , 6 - d i b r o m o - 3 , 3 - d i m e -
thyl-7-oxo-4-thia-1azabicyclo [3.2.0]heptan-2-yl)methyl)-
1H-1,2,3-triazole-4-carbonyl)-L-leucyl-L-phenylalaninate 
(TAP7f). Compound 8 was dissolved in THF, and CuI (0.5 
equiv) DIPEA (5 equiv) and penicillin azide 4 (1.1 equiv) 
were added. The mixture was stirred for 3 h. After solvent 
evaporation, the residue was purified by column chroma-
tography (hexane:AcOEt) to give TAP7f (2.79g, 74%). NMR 
spectral data of TAP7f were identical to those reported 
in the literature.2 1H NMR (CDCl3, 300 MHz) δ 0.91 (d, J= 
5.6 Hz, 3H, CH3), 0.92 (d, J= 5.6 Hz, 3H, CH
3), 1.57 (s, 3H, 
CH3), 1.60 (s, 3H, CH3), 1.59-1.76 (m, 3H, CH and CH2), 3.04 
(dd, J1= 13.7 Hz, J2= 6.3 Hz, 1H, CH2), 3.14 (dd, J1= 13.7 
Hz, J2= 5.7 Hz, 1H, CH2), 60 3.69 (s, 3H, OCH3), 4.37 (dd, 
J1= 13.3 Hz, J2= 10 Hz, 1H, CH2), 4.49 (dd, J1= 10 Hz, J2= 
3.9, 1H, CH), 4.60 (m, 1H, CH), 4.70 (dd, J1= 13.3Hz, J2= 
3.9, 1H, CH2), 4.87 (m, 1H, CH), 5.66 (s, 1H, CH), 6.75 (d, 
J= 8 Hz, 1H, NH), 7.04-7.15 (m, 5H, ArH), 7.38 (d, J= 8.2 
Hz, 1H, NH), 8.26 (s, 1H, CH). 13C NMR (CDCl3, 75 MHz) 
δ 21.9 (CH3), 22.9 (CH3), 24.5 (CH), 24.6 (CH3), 33.3 (CH3), 
37.9 (CH2), 40.7 (CH2), 48.4 (CH2), 51.3 (CH), 52.3 (CH), 53.2 
(CH) 58.5 (C), 63.7 (C), 67.9 (CH), 78.4 (CH), 126.2 (CH), 
127.0 (CH), 128.5 (CH), 129.2 (CH), 135.6 (C), 143.0 (C), 
159.7 (CO), 165.6 (CO), 171.0 (CO), 171.8 (CO). IR: (film) 
1797 cm-1 (β-lactam), 1744 cm-1 (CO ester), 1670 cm-1 (CO 
amide). HRMS-ESI (m/z): calcd for C27H34Br2N6NaO5S 
[M+Na]+: 735.05704; found: 735.05518.
CONCLUSION
In summary, an approach using solution phase chemistry 
for the synthesis of TAP7f has been developed. We have 
demonstrated that this new, five-step, procedure is a more 
efficient and economical route to synthesize the target mol-
ecule in large scale.
Full-scale optimization of the synthetic sequence is being 
investigated, especially to be able to eliminate chromato-
graphic purifications by more convenient methods.
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